Skip to content
value.today

Biolex Therapeutics, Inc.

Total raised
$25 M
3 rounds on record
Latest round
$6 M
May 2011
First round on record
Feb 2010
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Biolex Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2011$6 MNo. 3$2 to $10 million

Biolex Therapeutics, Inc.: Raise no. 3, May 2011

Investors in this round

13 investors had bought by the notice of Jun 9, 2011: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $7 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dale A. Sander · Executive Officer
  • David P. Spencer · Executive Officer
  • Jan P. Turek · Executive Officer, Director
  • Kurt Page Graves · Executive Officer, Director
  • David L. Castaldi · Director
  • Dennis J. Dougherty · Director
  • Jeffrey Thomas Leiden · Director
  • Kevin A. Bitterman · Director
  • Klaus Thomas Veitinger · Director
  • Liza Page Nelson · Director
  • P. Sherrill Neff · Director
  • W. Thomas Amick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jan P. Turek, President and CEO. Source: SEC Form D, newest notice filed Jun 9, 2011. Read the notice at the SEC.

debt, optionsSEC
Jul 2010$9 MNo. 2$2 to $10 million

Biolex Therapeutics, Inc.: Raise no. 2, Jul 2010

Investors in this round

13 investors had bought by the notice of Jul 30, 2010: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $10 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dale A. Sander · Executive Officer
  • David P. Spencer · Executive Officer
  • Glen A. Williams · Executive Officer
  • Jan P. Turek · Executive Officer, Director
  • David Sherrill Castaldi · Director
  • Dennis J. Dougherty · Director
  • Jeff Thomas Leiden · Director
  • Kevin A. Bitterman · Director
  • Klaus Thomas Veitinger · Director
  • Liza Sherrill Page Nelson · Director
  • P. Sherrill Neff · Director
  • W. Thomas Amick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jan Turek, President and CEO. Source: SEC Form D, newest notice filed Jul 30, 2010. Read the notice at the SEC.

debt, optionsSEC
Feb 2010$10 MNo. 1$10 to $50 million

Biolex Therapeutics, Inc.: Raise no. 1, Feb 2010

Investors in this round

25 investors had bought by the notice of Feb 23, 2010: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dale A. Sander · Executive Officer
  • David P. Spencer · Executive Officer
  • Glen A. Williams · Executive Officer
  • Jan P. Turek · Executive Officer, Director
  • David Sherrill Castaldi · Director
  • Dennis J. Dougherty · Director
  • Jeff Thomas Leiden · Director
  • Kevin A. Bitterman · Director
  • Klaus Thomas Veitinger · Director
  • Liza Sherrill Page Nelson · Director
  • P. Sherrill Neff · Director
  • W. Thomas Amick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Dale Sander, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 23, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Biolex Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2011).

    SEC Form D · Jun 2011

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2011

That is all the official record says: Biolex Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Biolex Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 25 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Biolex Therapeutics, Inc.
NameRoleNamed in
Dale A. SanderExecutive officerJun 2011
David P. SpencerExecutive officerJun 2011
Jan P. TurekExecutive officerJun 2011
Kurt Page GravesExecutive officerJun 2011
Glen A. WilliamsExecutive officerJul 2010
David L. CastaldiDirectorJun 2011
Dennis J. DoughertyDirectorJun 2011
Jan P. TurekDirectorJun 2011
Jeffrey Thomas LeidenDirectorJun 2011
Kevin A. BittermanDirectorJun 2011
Klaus Thomas VeitingerDirectorJun 2011
Kurt Page GravesDirectorJun 2011
Liza Page NelsonDirectorJun 2011
P. Sherrill NeffDirectorJun 2011
W. Thomas AmickDirectorJun 2011
David Sherrill CastaldiDirectorJul 2010
Jeff Thomas LeidenDirectorJul 2010
Liza Sherrill Page NelsonDirectorJul 2010